类风湿关节炎患者接受JAK抑制剂治疗中胃肠道穿孔的安全性关注:系统综述与网状Meta分析
本系统综述与网状Meta分析纳入23项随机对照试验共20023例类风湿关节炎患者,中位随访24周。JAK抑制剂治疗患者胃肠道穿孔总体发生率为0.19%(95%CI 0.10-0.35%),12,430例中发生24例。与csDMARDs相比,JAK抑制剂未显著增加胃肠道穿孔风险(RR 1.02;95%CI 0.41-2.56;I²=0.0%),网状Meta分析结果一致(RR 0.83;95%CI 0.37-1.84;P=0.64)。
要点
- JAK抑制剂治疗患者胃肠道穿孔总体发生率为0.19%(95%CI 0.10-0.35%),12,430例中发生24例。
- 与csDMARDs相比,JAK抑制剂未显著增加胃肠道穿孔风险(RR 1.02;95%CI 0.41-2.56;I²=0.0%)。
- 网状Meta分析显示JAK抑制剂与csDMARDs相比胃肠道穿孔风险无统计学显著增加(RR 0.83;95%CI 0.37-1.84;P=0.64)。
核心结论
- 在类风湿关节炎患者中,与csDMARDs相比,JAK抑制剂未与胃肠道穿孔风险增加相关。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Embase、Cochrane Central Register of Controlled Trials和ClinicalTrials.gov至2024年8月。
- 纳入比较JAK抑制剂与其他对照的随机对照试验,对象为年龄≥18岁的成年类风湿关节炎患者,并报告胃肠道穿孔。
- 共纳入23项随机对照试验,涉及20,023例患者,中位随访时间24周。
主要发现
- JAK抑制剂治疗患者胃肠道穿孔总体发生率为0.19%(95%CI 0.10-0.35%),12,430例中发生24例。
- 配对Meta分析显示,与csDMARDs相比,JAK抑制剂组胃肠道穿孔风险未显著增加(RR 1.02;95%CI 0.41-2.56;I²=0.0%)。
- 网状Meta分析结果与配对Meta分析一致,与csDMARDs相比,JAK抑制剂未统计学显著增加胃肠道穿孔风险(RR 0.83;95%CI 0.37-1.84;P=0.64),无不一致性(P=0.55)。
- JAK抑制剂(50.8%)与生物制剂DMARDs(77.0%)的SUCRA提示胃肠道穿孔风险较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastrointestinal perforation (GIP) is a rare and life-threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta-analysis approach. METHODS: A comprehensive literature search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov through August 2024. Included were randomized controlled trials (RCTs) comparing JAKi with other comparators in adult patients with RA (age ≥18 years) and reports of GIP. Risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Surface under the cumulative ranking curves (SUCRA) were used to rank interventions. RESULTS: A total of 23 RCTs involving 20,023 patients were included, with a median follow-up time of 24 weeks. The overall incidence of GIP among JAKi-treated patients was 0.19% (95% CI 0.10-0.35%), with 24 events occurring out of 12,430 patients. Pairwise meta-analysis showed that the risk of GIP among patients taking JAKi was not significantly increased compared to that in those taking conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (RR 1.02; 95% CI 0.41-2.56; I2 = 0.0%). The results of the network meta-analysis are consistent with the pairwise meta-analysis findings. Compared to csDMARDs, there was no statistically significant increase in GIP risk with JAKi (RR 0.83; 95% CI 0.37-1.84; P = 0.64) without inconsistency (P = 0.55). The SUCRA of JAKi (50.8%) and biologic DMARDs (77.0%) indicated a low risk of GIP. CONCLUSION: JAKi were not associated with an increased risk of GIP compared to csDMARDs in patients with RA.
引用
- Sathapanasiri T, Meraz M, Mokri H, et al. Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta-Analysis. Arthritis Care Res (Hoboken). 2025. PMID: 40254953. doi:10.1002/acr.25554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。